Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Top Cited Papers
Open Access
- 30 May 2008
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Hepatology
- Vol. 48 (3), 871-877
- https://doi.org/10.1002/hep.22428
Abstract
Biochemical response to ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis (PBC) is variable. It has been recently proposed that an alkaline phosphatase (ALP) decline of more than 40% in baseline value or a normal level after 1 year of UDCA treatment (Barcelona criteria) could serve as a good marker of long-term prognosis. Our aim was to define the best efficient set of biochemistries able to identify UDCA-treated patients at risk of death or liver transplantation (LT). The efficiency of several combinations of serum bilirubin, ALP, and aspartate aminotransferase (AST) threshold values to predict outcome was assessed after 1 year of treatment in 292 patients with PBC. Patients showing ALP P < 0.001). Patients were less well discriminated by the Barcelona criteria (79% versus 63%). Independent predictive factors of death or LT were baseline serum bilirubin level >1 mg/dL (relative risk [RR], 1.7), histologic stage ≥3 (RR, 1.5), interface hepatitis (RR, 1.9), and the absence of biochemical response (ALP >3 ULN or AST >2 ULN, or bilirubin >1 mg/dL) (RR, 2.3). Antinuclear antibodies against gp210 or Sp100 proteins were associated with death or LT in univariate but not in multivariate analysis. Conclusion: This study defines the best efficient biochemical response to UDCA, which, independent of baseline predictive factors, identifies patients with PBC with a good long-term prognosis. Patients who fail to achieve this response and those with interface hepatitis or advanced histological stage should be targeted for further therapeutic research. (HEPATOLOGY 2008.)Keywords
This publication has 25 references indexed in Scilit:
- Prognosis of Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cirrhosis. Results of a 10-Yr Cohort Study Involving 297 PatientsThe American Journal of Gastroenterology, 2006
- Excellent Long-Term Survival in Patients With Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic AcidGastroenterology, 2006
- The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosisGastroenterology, 2005
- Survival of anti-mitochondrial antibody-positive and -negative primary biliary cirrhosis patients on ursodeoxycholic acid treatment.Digestive Diseases and Sciences, 2004
- Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosisJournal of Hepatology, 2003
- Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosisJournal of Hepatology, 1999
- Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosisGastroenterology, 1997
- Ursodeoxycholic acid in the treatment of primary biliary cirrhosisGastroenterology, 1994
- The canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosisJournal of Hepatology, 1994
- A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary CirrhosisThe New England Journal of Medicine, 1991